bioRxiv · 10.1101/2021.04.15.439941
Loss of adipocyte phospholipase gene PLAAT3 causes lipodystrophy and insulin resistance due to inactivated arachidonic acid-mediated PPAR signaling
Abstract
PLAAT3 is a phospholipid modifying enzyme predominantly expressed in white adipose tissue (WAT). It is a candidate drug target as Plaat3 deficiency in mice protects against picornavirus infection and diet-induced obesity. We identified four patients with homozygous loss-of-function mutations in PLAAT3, presenting with partial lipodystrophy, severe insulin resistance and dyslipidemia. PLAAT3-deficient WAT showed a failure to liberate arachidonic acid (AA) from membrane phospholipids resulting in an inactive gene network downstream of adipogenesis master regulator and anti-diabetic drug target PPARG. These findings establish PLAAT3 deficiency in humans as a novel type of partial lipodystrophy due to an AA- and PPARG-dependent defect in WAT differentiation and function.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Schuermans, N., El Chehadeh, S., Hemelsoet, D., Bogaert, E., Debackere, E., Hilbert, P., Van Doninck, N., Taquet, M.-C., Rosseel, T., De Clercq, G., Van Haverbeke, C., Chanson, J.-B., Funalot, B., Authier, F.-J., Kaya, S., Terryn, W., Callens, S., Depypere, B., Van Dorpe, J., Program for Undiagnosed Diseases (UD-PrOZA),, Poppe, B., Depienne, C., Dermaut, B.. 2021-04-15. Loss of adipocyte phospholipase gene PLAAT3 causes lipodystrophy and insulin resistance due to inactivated arachidonic acid-mediated PPAR signaling. https://doi.org/10.1101/2021.04.15.439941
Cite the original work for its findings. Save a collection to share your selection of sources.